• Science & Technology Community

    NETPark Net is the innovation support network for companies operating within the Science, Engineering and Technology Sectors.Join TodayLogin
  • Business Services

    From Funding to IP Landscaping to Contract Opportunities, our suite of business tools & services are designed to accelerate your business growth.Join TodayLogin
  • Innovation Community

    Who do you know? This is where like-minded science and technology companies gather.Join TodayLogin
  • Your success is our Success

    Let’s grow your Business. At NETPark NET, we will give you competitive advantage.Join TodayLogin
  • 1
  • 2
  • 3
  • 4

Latest News from NETPark Net

What’s going on in the world of business for science, engineering and technology companies?


ReViral Announces Appointment of New Chief Executive Officer

Friday, 14 October 2016

ReViral Ltd, a biotechnology company, aiming to help patients infected with respiratory syncytial virus (RSV) by developing novel compounds, is pleased to announce the appointment of Eddy Littler as CEO. Eddy joins ReViral from Domainex, a UK-based drug discovery company, where as CEO he successfully delivered major growth in size, revenues, and profit during his nine years in charge. Eddy also managed the pre-clinical development of the Domainex drug pipeline.

Over his distinguished career, Eddy has held senior positions in research and management in the pharmaceutical & biotech industries as well as in academia. He
played a leading role in the development of several marketed drugs for herpes viruses, influenza, and viral hepatitis. While leading the antiviral team at Medivir, he played a principal role in out-licensing Simeprevir, a treatment for hepatitis C to J&J. Dr. Littler holds a Ph.D. from the University of Leeds, UK and is an expert in virology and drug discovery.

"We are delighted that Eddy Littler is joining ReViral as Chief Executive Officer," commented Ken Powell, Chairman of ReViral. "He is a tried and tested entrepreneurial business leader. His industry knowledge, track record and strong relationships are ideal skills to bring to ReViral. Eddy’s expertise in the antiviral area, leadership and experience are of significant benefit to the Company."

Eddy Littler commented, "I am pleased to be joining ReViral as CEO at this critical time in its development where I can help move the Company’s lead programme RV521, forward into clinical development. The ground breaking projects and drug candidates at ReViral for treating RSV can translate into significant value for patients,
clinicians, and ReViral shareholders and I look forward to contributing to the success of the Company."


What are your views on this story?

blog comments powered by Disqus

Latest News

Latest Blog

What Our Members Say

  • NETPark Net offers an amazing range of services and we have made profitable use of the many meetings arranged. Even the breakfast meetings have been more helpful than we could have imagined. Plus some great contacts have been made ! NETPark Net FeedbackSteve CrightonPollywood
  • I have been to a couple of the Breakfast Networking events. The speakers have been excellent and one in particular has led to us working with them on a commercial basis. It's often the discussions that develop that generate interesting ideas and leads in directions you wouldn't have normally considered. NETPark Net FeedbackMoira HopkinsPolyphotonix
  • 1